Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18206
Country/Region: Kenya
Year: 2018
Main Partner: Kenya Conference of Catholic Bishops
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $9,722,497 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $138,303
Care: TB/HIV (HVTB) $684,072
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $90,136
Testing: HIV Testing and Counseling (HVCT) $874,199
Sexual Prevention: Other Sexual Prevention (HVOP) $114,800
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $312,521
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $6,913,339
Treatment: Pediatric Treatment (PDTX) $595,127
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST <5, Unknown Sex, Negative 2019 57
HTS_TST 15-19, Female, Negative 2019 363
HTS_TST 15-19, Male, Negative 2019 184
HTS_TST 20-24, Female, Negative 2019 1,252
HTS_TST 20-24, Male, Negative 2019 586
HTS_TST 25-29, Female, Negative 2019 145
HTS_TST 25-29, Female, Negative 2019 1,465
HTS_TST 25-29, Female, Negative 2019 58
HTS_TST 25-29, Female, Negative 2019 2,766
HTS_TST 25-29, Female, Negative 2019 2,181
HTS_TST 25-29, Female, Negative 2019 88
HTS_TST 25-29, Female, Negative 2019 45
HTS_TST 25-29, Female, Negative 2019 782
HTS_TST 25-29, Male, Negative 2019 1,049
HTS_TST 25-29, Male, Negative 2019 3,213
HTS_TST 25-29, Male, Negative 2019 101
HTS_TST 25-29, Male, Negative 2019 26
HTS_TST 25-29, Male, Negative 2019 11,588
HTS_TST 25-29, Male, Negative 2019 295
HTS_TST 25-29, Male, Negative 2019 62
HTS_TST 25-29, Male, Negative 2019 3,548
HTS_TST 30-34, Female, Negative 2019 165
HTS_TST 30-34, Female, Negative 2019 1,673
HTS_TST 30-34, Female, Negative 2019 65
HTS_TST 30-34, Female, Negative 2019 3,047
HTS_TST 30-34, Female, Negative 2019 2,181
HTS_TST 30-34, Female, Negative 2019 102
HTS_TST 30-34, Female, Negative 2019 42
HTS_TST 30-34, Female, Negative 2019 893
HTS_TST 30-34, Male, Negative 2019 1,260
HTS_TST 30-34, Male, Negative 2019 3,855
HTS_TST 30-34, Male, Negative 2019 122
HTS_TST 30-34, Male, Negative 2019 32
HTS_TST 30-34, Male, Negative 2019 13,953
HTS_TST 30-34, Male, Negative 2019 352
HTS_TST 30-34, Male, Negative 2019 65
HTS_TST 30-34, Male, Negative 2019 4,260
HTS_TST 35-39, Female, Negative 2019 40
HTS_TST 35-39, Female, Negative 2019 417
HTS_TST 35-39, Female, Negative 2019 17
HTS_TST 35-39, Female, Negative 2019 1,126
HTS_TST 35-39, Female, Negative 2019 2,181
HTS_TST 35-39, Female, Negative 2019 24
HTS_TST 35-39, Female, Negative 2019 51
HTS_TST 35-39, Female, Negative 2019 223
HTS_TST 35-39, Male, Negative 2019 1,260
HTS_TST 35-39, Male, Negative 2019 3,855
HTS_TST 35-39, Male, Negative 2019 122
HTS_TST 35-39, Male, Negative 2019 32
HTS_TST 35-39, Male, Negative 2019 12,495
HTS_TST 35-39, Male, Negative 2019 352
HTS_TST 35-39, Male, Negative 2019 90
HTS_TST 35-39, Male, Negative 2019 4,260
HTS_TST 40-49, Female, Negative 2019 223
HTS_TST 40-49, Female, Negative 2019 40
HTS_TST 40-49, Female, Negative 2019 417
HTS_TST 40-49, Female, Negative 2019 17
HTS_TST 40-49, Female, Negative 2019 1,126
HTS_TST 40-49, Female, Negative 2019 2,181
HTS_TST 40-49, Female, Negative 2019 24
HTS_TST 40-49, Female, Negative 2019 41
HTS_TST 40-49, Male, Negative 2019 1,420
HTS_TST 40-49, Male, Negative 2019 420
HTS_TST 40-49, Male, Negative 2019 1,286
HTS_TST 40-49, Male, Negative 2019 41
HTS_TST 40-49, Male, Negative 2019 10
HTS_TST 40-49, Male, Negative 2019 4,165
HTS_TST 40-49, Male, Negative 2019 116
HTS_TST 40-49, Male, Negative 2019 83
HTS_TST 50+, Female, Negative 2019 13
HTS_TST 50+, Male, Negative 2019 60
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 296,189
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 31
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 51
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 106
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 164
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 8
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 5
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 27
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 49
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 93
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 156
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 20
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 91
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 3,656
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 7,629
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 34
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 876
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 3,736
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 955
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 615
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 1,484
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 916
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 5,113
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 4,963
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 20
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 211
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 164
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 711
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 185
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 119
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 2,998
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 2,497
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 10,326
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 7,988
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 209
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 644
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 2,458
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 639
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 406
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 7,684
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 10,744
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 36,392
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 25,171
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 563
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 2,083
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 2,613
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 27
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 33
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 29
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 47
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 59
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 47
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 59
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 37
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 68
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 272
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 1,480
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 359
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 247
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 5,596
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 2,874
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 19,273
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 9,205
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 112
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 710
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 546
HTS_TST_POS 15-19, Female, Positive 2019 1
HTS_TST_POS 20-24, Female, Positive 2019 4
HTS_TST_POS 20-24, Male, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 28
HTS_TST_POS 25-29, Female, Positive 2019 16
HTS_TST_POS 25-29, Female, Positive 2019 3
HTS_TST_POS 25-29, Female, Positive 2019 38
HTS_TST_POS 25-29, Female, Positive 2019 317
HTS_TST_POS 25-29, Female, Positive 2019 20
HTS_TST_POS 25-29, Female, Positive 2019 23
HTS_TST_POS 25-29, Male, Positive 2019 167
HTS_TST_POS 25-29, Male, Positive 2019 52
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 279
HTS_TST_POS 25-29, Male, Positive 2019 27
HTS_TST_POS 25-29, Male, Positive 2019 117
HTS_TST_POS 30-34, Female, Positive 2019 32
HTS_TST_POS 30-34, Female, Positive 2019 18
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 42
HTS_TST_POS 30-34, Female, Positive 2019 32
HTS_TST_POS 30-34, Female, Positive 2019 20
HTS_TST_POS 30-34, Female, Positive 2019 27
HTS_TST_POS 30-34, Male, Positive 2019 200
HTS_TST_POS 30-34, Male, Positive 2019 63
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 336
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 29
HTS_TST_POS 30-34, Male, Positive 2019 139
HTS_TST_POS 35-39, Female, Positive 2019 8
HTS_TST_POS 35-39, Female, Positive 2019 4
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 15
HTS_TST_POS 35-39, Female, Positive 2019 26
HTS_TST_POS 35-39, Female, Positive 2019 22
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Male, Positive 2019 139
HTS_TST_POS 35-39, Male, Positive 2019 200
HTS_TST_POS 35-39, Male, Positive 2019 63
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 316
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 40
HTS_TST_POS 40-49, Female, Positive 2019 6
HTS_TST_POS 40-49, Female, Positive 2019 8
HTS_TST_POS 40-49, Female, Positive 2019 4
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 15
HTS_TST_POS 40-49, Female, Positive 2019 16
HTS_TST_POS 40-49, Female, Positive 2019 19
HTS_TST_POS 40-49, Male, Positive 2019 45
HTS_TST_POS 40-49, Male, Positive 2019 67
HTS_TST_POS 40-49, Male, Positive 2019 21
HTS_TST_POS 40-49, Male, Positive 2019 105
HTS_TST_POS 40-49, Male, Positive 2019 36
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) ANC: 10-14, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 74
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 290
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 55
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 215
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 149
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 724
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 502
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 32
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 57
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 42
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 197
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 133
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 195
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 273
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 904
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 660
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 53
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 27
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 27
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 170
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 104
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 581
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 335
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 23
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14 2019 96
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 2019 156
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24 2019 132
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14 2019 22
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17 2019 15
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24 2019 8
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14 2019 716
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17 2019 1,343
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24 2019 949
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14 2019 83
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17 2019 53
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24 2019 34
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 2019 980
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17 2019 206
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24 2019 99
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14 2019 292
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17 2019 182
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24 2019 126
PMTCT_ART Already on ART at beginning of current pregnancy 2019 3,141
PMTCT_ART New on ART 2019 754
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 3,895
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 23,760
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 305
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 123
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 428
PMTCT_EID Sum of Infant Age disaggregates 2019 428
PMTCT_STAT 25-29, Female 2019 2,677
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 497
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 2,101
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 79
PMTCT_STAT 30-34, Female 2019 3,058
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 497
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 2,482
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 79
PMTCT_STAT 35-39, Female 2019 2,677
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 497
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 2,101
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 79
PMTCT_STAT 40-49, Female 2019 2,677
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 497
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 2,101
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 79
PMTCT_STAT By Age (Numerator): 10-14 2019 94
PMTCT_STAT By Age (Numerator): 15-19 2019 3,923
PMTCT_STAT By Age (Numerator): 20-24 2019 8,629
PMTCT_STAT By Age (Numerator): 50+ 2019 25
PMTCT_STAT By Number of known positives: 10-14 2019 2
PMTCT_STAT By Number of known positives: 15-19 2019 248
PMTCT_STAT By Number of known positives: 20-24 2019 903
PMTCT_STAT By Number of new negative: 10-14 2019 89
PMTCT_STAT By Number of new negative: 15-19 2019 3,531
PMTCT_STAT By Number of new negative: 20-24 2019 7,435
PMTCT_STAT By Number of new negative: 50+ 2019 25
PMTCT_STAT By Number of new positives: 10-14 2019 3
PMTCT_STAT By Number of new positives: 15-19 2019 144
PMTCT_STAT By Number of new positives: 20-24 2019 291
PMTCT_STAT Number of new ANC and L&D clients 2019 24,042
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 23,760
PMTCT_STAT_den 25-29, Female 2019 2,692
PMTCT_STAT_den 30-34, Female 2019 2,692
PMTCT_STAT_den 35-39, Female 2019 2,692
PMTCT_STAT_den 40-49, Female 2019 2,692
PMTCT_STAT_den By Age (Denominator): <15-19 2019 4,239
PMTCT_STAT_den By Age (Denominator): 10-14 2019 113
PMTCT_STAT_den By Age (Denominator): 20-24 2019 8,892
PMTCT_STAT_den By Age (Denominator): 50+ 2019 30
PP_PREV Age/sex: 10-14 Female 2019 1,776
PP_PREV Age/sex: 10-14 Male 2019 1,540
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 3,316
PP_PREV Sum of Age/Sex disaggregates 2019 3,316
PrEP_NEW 25-29, Female 2019 82
PrEP_NEW 25-29, Male 2019 34
PrEP_NEW 30-34, Female 2019 59
PrEP_NEW 30-34, Male 2019 47
PrEP_NEW 35-39, Female 2019 58
PrEP_NEW 35-39, Male 2019 46
PrEP_NEW 40-49, Female 2019 58
PrEP_NEW 40-49, Male 2019 34
PrEP_NEW Female 15-19 2019 141
PrEP_NEW Female 20-24 2019 482
PrEP_NEW Female 50+ 2019 25
PrEP_NEW FSW 2019 165
PrEP_NEW Male 15-19 2019 12
PrEP_NEW Male 20-24 2019 72
PrEP_NEW Male 50+ 2019 25
PrEP_NEW MSM 2019 82
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 1,175
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 747
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 672
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 1,419
TB_PREV By Age/Sex (Numerator): <15, Female 2019 415
TB_PREV By Age/Sex (Numerator): <15, Male 2019 480
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 5,053
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 2,681
TB_PREV IPT, Life-long ART, New, Positive 2019 3,246
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 8,629
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 9,268
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 453
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 568
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 5,419
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 2,828
TB_PREV_den IPT, Life-long ART, New, Positive 2019 9,268
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 100
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,015
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 78
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 960
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 2,153
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 2,153
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 112
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 987
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 81
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 973
TX_CURR 25-29, Female, Positive 2019 12,452
TX_CURR 25-29, Male, Positive 2019 4,177
TX_CURR 30-34, Female, Positive 2019 9,448
TX_CURR 30-34, Male, Positive 2019 6,526
TX_CURR 35-39, Female, Positive 2019 9,446
TX_CURR 35-39, Male, Positive 2019 6,526
TX_CURR 40-49, Female, Positive 2019 6,444
TX_CURR 40-49, Male, Positive 2019 6,526
TX_CURR Age/Sex: <1 2019 89
TX_CURR Age/Sex: <1-9 2019 3,988
TX_CURR Age/Sex: 10-14 Female 2019 1,384
TX_CURR Age/Sex: 10-14 Male 2019 1,199
TX_CURR Age/Sex: 15-19 Female 2019 2,919
TX_CURR Age/Sex: 15-19 Male 2019 1,389
TX_CURR Age/Sex: 20-24 Female 2019 8,140
TX_CURR Age/Sex: 20-24 Male 2019 1,855
TX_CURR Age/Sex: 50+ Female 2019 5,151
TX_CURR Age/Sex: 50+ Male 2019 2,351
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 90,010
TX_CURR Sum of age/sex disaggregates 2019 4,308
TX_NEW 25-29, Female, Positive 2019 152
TX_NEW 25-29, Male, Positive 2019 674
TX_NEW 30-34, Female, Positive 2019 172
TX_NEW 30-34, Male, Positive 2019 827
TX_NEW 35-39, Female, Positive 2019 43
TX_NEW 35-39, Male, Positive 2019 816
TX_NEW 40-49, Female, Positive 2019 43
TX_NEW 40-49, Male, Positive 2019 272
TX_NEW Breastfeeding status 2019 213
TX_NEW By Age/Sex: <1 2019 137
TX_NEW By Age/Sex: 1-9 2019 116
TX_NEW By Age/Sex: 10-14 Female 2019 29
TX_NEW By Age/Sex: 10-14 Male 2019 18
TX_NEW By Age/Sex: 15-19 Female 2019 751
TX_NEW By Age/Sex: 15-19 Male 2019 569
TX_NEW By Age/Sex: 20-24 Female 2019 2,591
TX_NEW By Age/Sex: 20-24 Male 2019 1,814
TX_NEW By Age/Sex: 50+ Female 2019 22
TX_NEW By Age/Sex: 50+ Male 2019 130
TX_NEW By Key populations: People who inject drugs (PWID) 2019 2
TX_NEW FSW 2019 64
TX_NEW MSM 2019 10
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 9,176
TX_NEW People in prisons and other enclosed settings 2019 49
TX_NEW Pregnancy status 2019 819
TX_NEW Sum of Age/Sex disaggregates 2019 5,924
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 89,402
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 1,858
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 304
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,605
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 262
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 50,240
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 8,200
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 23,163
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 3,777
TX_PVLS_den Denominator: Indication: Routine 2019 76,862
TX_PVLS_den Denominator: Indication: Targeted 2019 12,540
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 578
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 258
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 12,099
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 5,406
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 18,341
TX_RET Numerator by Status: Breastfeeding 2019 562
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 19,983
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 549
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 321
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 12,799
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 6,314
TX_RET_den Denominator by Status: Breastfeeding 2019 571
TX_RET_den Denominator by Status: Pregnant 2019 1,359
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 90,006
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 4,237
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 4,671
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 55,382
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 25,716
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 6,024
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 641
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 6,909
Cross Cutting Budget Categories and Known Amounts Total: $2,400,274
Gender: Gender Based Violence (GBV) $240,000
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Gender: Gender Equality $240,000
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Human Resources for Health $1,425,007
Motor Vehicles: Purchased $152,028
Adolescent Girls and Young Women (AGYW) $343,239